Ensol Biosciences Inc
140610
Company Profile
Business description
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.
Contact
51, Techno 10-ro
Yuseong-gu
Daejeon34036
KORT: +82 429394500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
41
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,768.60 | 1.60 | -0.02% |
| CAC 40 | 7,790.27 | 14.40 | -0.18% |
| DAX 40 | 24,323.58 | 47.10 | 0.19% |
| Dow JONES (US) | 42,462.67 | 34.93 | 0.08% |
| FTSE 100 | 8,811.04 | 9.75 | 0.11% |
| HKSE | 23,906.97 | 252.94 | 1.07% |
| NASDAQ | 19,385.80 | 74.69 | -0.38% |
| Nikkei 225 | 37,554.49 | 192.96 | -0.51% |
| NZX 50 Index | 12,577.15 | 82.44 | 0.66% |
| S&P 500 | 5,960.09 | 10.72 | -0.18% |
| S&P/ASX 200 | 8,538.90 | 2.90 | -0.03% |
| SSE Composite Index | 3,384.10 | 7.90 | 0.23% |